Acquisition of Biovotion establishes Biovitals® as the most comprehensive predictive digital therapeutics solution for healthcare providers, payers and pharmaceutical companies by combining best-in-class medical data collection and digital therapeutics solutions into one platform
BOSTON and ZÜRICH, SWITZERLAND, Nov. 18, 2019 – Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. The acquisition includes all of Biovotion’s assets, including the market-leading Everion® biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or hand.
The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals® ecosystem. Clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings.
Biofourmis’ clinically validated and FDA-approved software-based digital therapeutics that are part of the growing Biovitals® ecosystem are already being leveraged across multiple segments of healthcare and life sciences. Combining Biovotion’s best-in-class wearables with Biofourmis’ digital therapeutics platform and its leading artificial intelligence (AI)-driven predictive analytics creates the most comprehensive digital therapeutics solution on the market.
The lead product among Biovotion’s wearables is the clinical-grade Everion® device, which is a multi-sensor platform worn on the arm capable of measuring 22 clinical and non-clinical parameters in real time, such as heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature, actigraphy (rest/activity cycles), motion intensity and steps, energy expenditure and sleep quality. Building on Everion’s current market-leading wearable, the next-generation Everion® device is already under development and will have the ability to capture additional vital parameters, including continuous blood pressure trends.
Everion® rounds out Biofourmis’ Biovitals® ecosystem, a highly sophisticated personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. The multi-parameter physiology data captured from Everion® will be an integral component of Biovitals’® digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain. These products are tailored to help providers identify the best therapies for managing chronic conditions before patients’ health worsens, potentially reducing hospital readmissions and decreasing the need for emergency department visits to reduce costs.
“Biovotion had been a trusted partner for many years as we have leveraged each other’s technologies across numerous clinical, commercial and research applications,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “We are thrilled to add Everion® to the Biovitals® ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events, and improving clinical outcomes—and ultimately reducing healthcare costs.”
The entire Biovotion team will be incorporated into the Biofourmis family under the name “Biofourmis AG” in Zürich, Switzerland. The team brings deep knowledge and insights for developing and launching cutting-edge clinical-grade wearables, as well as an impressive roster of more than 80 current and previous partners—including large global pharmaceutical companies and contract research organizations (CROs), healthcare providers such as Mayo Clinic and the University Hospital of Basel, and technology partners such as IBM Research and Microsoft.
Now that the Everion® and Biovitals® solutions are one, securing future clinical, pharmaceutical and other agreements will be more efficient and expedited, offering potential clients a single, experienced and proven digital therapeutics partner for all their needs.
“Being part of the Biofourmis family will allow us to accelerate the development of our innovative platform to collect continuous vital data from patients,” said Dr. Markus Christen, Biovotion Chairman and CEO. “Certainly, providers, payers, managed care organizations and pharmaceutical companies will benefit tremendously from our synergies—but more importantly, this agreement will help more patients across the globe achieve optimal outcomes.”
Biofourmis, a fast-growing global leader in digital therapeutics, discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and potentially complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.
For more information visit: www.biofourmis.com
Amendola Communications for Biofourmis